


DCC-3116

Chemical Properties

CAS No. : 2543673-19-2
 Formula: C₂₆H₃₆F₃N₇O₂
 Molecular Weight: 535.61
 Appearance: Solid
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	DCC-3116 is an orally active, selective and potent ULK1/2 inhibitor with anticancer activity. DCC-3116 inhibits autophagy and can be used in cancer research.
Targets(IC50)	Autophagy, Ras, Kras
In vitro	100 nM DCC-3116 alone inhibited NCI-H2122 and Calu-1 cell proliferation and reduced pS318-ATG13 expression, and DCC-3116 in combination with sotorasib showed synergistic inhibition of human lung cancer cell proliferation driven by the KRAS G12C mutation in vitro. [1]
In vivo	Daily oral or intraperitoneal administration of 3 or 30 mg/kg DCC-3116 for 56 consecutive days alone or in combination with Sotorasib inhibited tumor growth in a mouse model of NSCLC lung cancer. [1]

Solubility Information

Solubility	DMSO: 100 mg/mL (186.7 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.16 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.867 mL	9.3352 mL	18.6703 mL
5 mM	0.3734 mL	1.867 mL	3.7341 mL
10 mM	0.1867 mL	0.9335 mL	1.867 mL
50 mM	0.0373 mL	0.1867 mL	0.3734 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Ghazi PC, et al. Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancer. bioRxiv [Preprint]. 2024 Jun 17:2024.02.06.579200.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481